Bank of New York Mellon
FLGT icon

Bank of New York Mellon’s Fulgent Genetics FLGT Stock Holding History

Bank of New York Mellon’s Portfolio FLGT Stock Details FLGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.55M Sell
75,639
-655
-0.9% -$11.1K ﹤0.01% 3101
2026
Q1 		$1.21M Sell
76,294
-8,453
-10% -$183K ﹤0.01% 3094
2025
Q4 		$2.23M Buy
84,747
+5,666
+7% +$147K ﹤0.01% 2768
2025
Q3 		$1.79M Buy
79,081
+1,674
+2% +$34.5K ﹤0.01% 2861
2025
Q2 		$1.54M Sell
77,407
-4,912
-6% -$95.7K ﹤0.01% 2882
2025
Q1 		$1.39M Sell
82,319
-67,579
-45% -$1.15M ﹤0.01% 2866
2024
Q4 		$2.77M Sell
149,898
-38,099
-20% -$744K ﹤0.01% 2608
2024
Q3 		$4.09M Sell
187,997
-13,204
-7% -$295K ﹤0.01% 2393
2024
Q2 		$3.95M Buy
201,201
+55,020
+38% +$1.15M ﹤0.01% 2450
2024
Q1 		$3.17M Sell
146,181
-9,748
-6% -$242K ﹤0.01% 2531
2023
Q4 		$4.51M Sell
155,929
-57,817
-27% -$1.55M ﹤0.01% 2421
2023
Q3 		$5.72M Sell
213,746
-7,770
-4% -$265K ﹤0.01% 2244
2023
Q2 		$8.2M Sell
221,516
-4,843
-2% -$169K ﹤0.01% 2047
2023
Q1 		$7.07M Sell
226,359
-5,052
-2% -$163K ﹤0.01% 2115
2022
Q4 		$6.89M Sell
231,411
-9,541
-4% -$341K ﹤0.01% 2149
2022
Q3 		$9.19M Buy
240,952
+10,342
+4% +$518K ﹤0.01% 1946
2022
Q2 		$12.6M Sell
230,610
-19,553
-8% -$1.07M ﹤0.01% 1806
2022
Q1 		$15.6M Sell
250,163
-1,483
-0.6% -$97.6K ﹤0.01% 1818
2021
Q4 		$25.3M Buy
251,646
+44,332
+21% +$3.9M ﹤0.01% 1583
2021
Q3 		$18.6M Buy
207,314
+13,890
+7% +$1.26M ﹤0.01% 1763
2021
Q2 		$17.8M Buy
193,424
+24,758
+15% +$1.98M ﹤0.01% 1799
2021
Q1 		$16.3M Buy
168,666
+32,183
+24% +$3.32M ﹤0.01% 1815
2020
Q4 		$7.11M Buy
136,483
+39,052
+40% +$1.63M ﹤0.01% 2182
2020
Q3 		$3.9M Buy
97,431
+23,372
+32% +$732K ﹤0.01% 2347
2020
Q2 		$1.19M Buy
74,059
+21,516
+41% +$329K ﹤0.01% 2995
2020
Q1 		$566K Buy
+52,543
New +$732K ﹤0.01% 3297
2017
Q2 		– Sell
-11,230
Closed -$122K – 4313
2017
Q1 		$122K Buy
+11,230
New +$133K ﹤0.01% 3980

Other funds holding FLGT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
TG
TCW Group Los Angeles, California $14.9B AUM 46.29% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return

Bank of New York Mellon's FLGT Position: Q2 2026 in Review

Bank of New York Mellon reduced its Fulgent Genetics (FLGT) stake by 0.86% in Q2 2026, selling an estimated $11.1K and leaving 75,639 shares worth $1.55M. The position accounts for ﹤0.01% of the portfolio, ranked #3101.

Bank of New York Mellon first reported a position in FLGT in Q1 2017 and has held it in 27 quarters since. The position peaked at $25.3M in Q4 2021. 69 funds tracked by Wall St. Rank hold FLGT as of Q2 2026.

  • Bank of New York Mellon held 75,639 shares of Fulgent Genetics worth $1.55M as of Q2 2026.
  • Bank of New York Mellon sold 655 Fulgent Genetics shares in Q2 2026, an estimated $11.1K.
  • Fulgent Genetics made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #3101 holding.
  • Bank of New York Mellon first reported a position in Fulgent Genetics in Q1 2017 and has held it in 27 quarters since.
  • Bank of New York Mellon's Fulgent Genetics position peaked at $25.3M in Q4 2021.
  • 69 funds tracked by Wall St. Rank held Fulgent Genetics as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.